Pivotal Phase 3 study, NANORAY-312, actively enrolling elderly, LA-HNSCC patients ineligible for cisplatin across ~50 sites as LianBio enrolls first patient and continues to ramp up site activation in Asia and Nanobiotix adds European sites, and begins recruitment in the US Reported €63.0 million in cash and cash equivalents as of June 30, 2022 which,…
/cloudfront-us-east-2.images.arcpublishing.com/reuters/O5XSUGS2SFOSRG5NOWI3ZOLLUY.jpg "Credit Suisse poised to revamp senior management, NZZ am Sonntag reports")
The logo of Swiss bank Credit Suisse is seen at an office building in Zurich, Switzerland February 21, 2022. REUTERS/Arnd Wiegmann/File Photo Register now for FREE unlimited access to Reuters.com Register ZURICH, April 24 (Reuters) – Loss-making Credit Suisse (CSGN.S) could shake up senior management as new Chairman Axel Lehmann seeks to put the embattled…
Financial results demonstrate strong fundamentals Twenty key clinical milestones achieved year-to-date, including positive data readouts for lemzoparlimab, uliledlimab and felzartamab Seven business development deals, including a US$315M strategic commercial partnership with Jumpcan on eftansomatropin alfa Global pipeline comprised of 10 clinical stage assets, mostly in phase 2 and phase 3 clinical trials, and 10 pre-clinical…